Form 4: BioCardia CEO Peter Altman Boosts Stake Through Private Placement
Insider Transaction Report
BioCardia, Inc. CEO Peter Altman acquired 24,096 shares of common stock and an equal number of warrants through a private placement on June 30, 2025, significantly increasing his direct beneficial ownership.
Summary
- Peter Altman, BioCardia's President and CEO, Director, and 10% Owner, acquired securities on June 30, 2025.
- He purchased 24,096 shares of common stock at a price of $2.075 per share.
- Concurrently, he received 24,096 warrants, each exercisable at $1.95, with an expiration date of June 30, 2030.
- This acquisition was part of a private placement that included certain qualified institutional buyers and institutional accredited investors.
- Following the transaction, Peter Altman directly beneficially owns 165,862 shares of common stock and 95,612 warrants.
Sentiment
Score: 8
Explanation: The acquisition by the CEO through a private placement indicates strong insider confidence and successful capital raising from institutional investors, which is a positive signal.
Positives
- BioCardia's President and CEO, Peter Altman, increased his direct stake in the company by purchasing 24,096 shares and 24,096 warrants, signaling strong confidence in the company's future prospects.
- The acquisition was part of a private placement, indicating the company successfully raised capital from institutional investors and key management.
Related Party Transactions
- Peter Altman, who serves as President and CEO, Director, and 10% Owner of BioCardia, Inc., acquired common stock and warrants from the company as part of a private placement.
Stakeholder Impact
- Shareholders may interpret the CEO's increased stake as a positive indicator of management's confidence in the company's future.
- The private placement, which included the CEO's participation, suggests a successful capital raise that could strengthen the company's financial position.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of transaction, closing of private placement and acquisition of common stock and warrants by Peter Altman. |
| 07/02/2025 | Date the Form 4 was signed by David McClung, by power of attorney. |
| 06/30/2030 | Expiration date of the warrants acquired by Peter Altman. |
Recommendation
buyKeywords
BioCardia, BCDA, Peter Altman, insider trading, private placement, common stock, warrants, CEO, director, beneficial ownership, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.